Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Pebblebrook Hotel Trust is a reit-hotel & motel business based in the US. Pebblebrook Hotel Trust shares (PEB) are listed on the NYSE and all prices are listed in US Dollars. Pebblebrook Hotel Trust employs 53 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$23.31|
|52-week range||$11.66 - $26.40|
|50-day moving average||$21.72|
|200-day moving average||$23.06|
|Wall St. target price||$25.46|
|Dividend yield||$0.04 (0.17%)|
|Earnings per share (TTM)||$-3.50|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-09-17)||3.23%|
|1 month (2021-08-26)||10.95%|
|3 months (2021-06-25)||-2.88%|
|6 months (2021-03-26)||-7.68%|
|1 year (2020-09-25)||91.69%|
|2 years (2019-09-26)||-15.42%|
|3 years (2018-09-26)||36.23|
|5 years (2016-09-26)||26.14|
Valuing Pebblebrook Hotel Trust stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Pebblebrook Hotel Trust's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Pebblebrook Hotel Trust's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.48. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Pebblebrook Hotel Trust's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Pebblebrook Hotel Trust's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $28.2 million.
The EBITDA is a measure of a Pebblebrook Hotel Trust's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$398.1 million|
|Gross profit TTM||$-50,871,000|
|Return on assets TTM||-2.9%|
|Return on equity TTM||-12.6%|
|Market capitalisation||$3.1 billion|
TTM: trailing 12 months
There are currently 14.5 million Pebblebrook Hotel Trust shares held short by investors – that's known as Pebblebrook Hotel Trust's "short interest". This figure is 2.7% down from 14.9 million last month.
There are a few different ways that this level of interest in shorting Pebblebrook Hotel Trust shares can be evaluated.
Pebblebrook Hotel Trust's "short interest ratio" (SIR) is the quantity of Pebblebrook Hotel Trust shares currently shorted divided by the average quantity of Pebblebrook Hotel Trust shares traded daily (recently around 999557.22183829). Pebblebrook Hotel Trust's SIR currently stands at 14.47. In other words for every 100,000 Pebblebrook Hotel Trust shares traded daily on the market, roughly 14470 shares are currently held short.
However Pebblebrook Hotel Trust's short interest can also be evaluated against the total number of Pebblebrook Hotel Trust shares, or, against the total number of tradable Pebblebrook Hotel Trust shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Pebblebrook Hotel Trust's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 Pebblebrook Hotel Trust shares in existence, roughly 110 shares are currently held short) or 0.1116% of the tradable shares (for every 100,000 tradable Pebblebrook Hotel Trust shares, roughly 112 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Pebblebrook Hotel Trust.
Find out more about how you can short Pebblebrook Hotel Trust stock.
We're not expecting Pebblebrook Hotel Trust to pay a dividend over the next 12 months.
Over the last 12 months, Pebblebrook Hotel Trust's shares have ranged in value from as little as $11.664 up to $26.3978. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Pebblebrook Hotel Trust's is 2.0377. This would suggest that Pebblebrook Hotel Trust's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Pebblebrook Hotel Trust (NYSE: PEB) is a publicly traded real estate investment trust (REIT) and the largest owner of urban and resort lifestyle hotels in the United States. The Company owns 53 hotels, totaling approximately 13,200 guestrooms across 14 urban and resort markets, with a focus on the west coast gateway cities. .
Everything we know about the Enfusion IPO, plus information on how to buy in.
Everything we know about the Intuity Medical IPO, plus information on how to buy in.
Everything we know about the Pyxis Oncology IPO, plus information on how to buy in.
Everything we know about the AEON Biopharma IPO, plus information on how to buy in.
Everything we know about the IHS Holding Ltd IPO, plus information on how to buy in.
Everything we know about the BT Brands IPO, plus information on how to buy in.
Everything we know about the Immix IPO, plus information on how to buy in.
Everything we know about the Keter Group SA IPO, plus information on how to buy in.
Everything we know about the Theseus Pharmaceuticals IPO, plus information on how to buy in.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq on Sep. 20, 2021
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.